GILD · Earnings call · 2026Q3T · Full report

Product Launch and Transition

GILEAD SCIENCES, INC. · 2026-10-29 · Importance 31 · Surprise 42

Gilead launched Bixlenvo in late August and said the launch was on track with expectations, while noting it was still early. Management reported strong awareness and said Bixlenvo was ahead of recent competitor launches at comparable post-launch time points. The company plans to continue building access and field awareness among patients with complex regimens and virally suppressed patients considering a switch.

Key facts

• Bixlenvo launched in the United States late in the third quarter of 2026 after receiving U.S. approval in August.
• Bixlenvo uptake among virally suppressed people with HIV on complex regimens was in line with Gilead's expectations early in its launch.
• Gilead's Bixlenvo launch, which began in late August 2026, was on track versus expectations.
• At similar post-launch time points, Gilead's Bixlenvo launch was well ahead of recent competitor launches.
• Gilead intends to continue building access and awareness for Bixlenvo among complex-regimen and virally suppressed switch patients.